iLIVER最新文献

{"title":"Transarterial chemoembolization plus radiofrequency ablation: One of the effective interventions for hepatocellular carcinoma","authors":"Yong Xie, Jian Wang, Yinghua Zou","doi":"10.1016/j.iliver.2024.100114","DOIUrl":"10.1016/j.iliver.2024.100114","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100114"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000392/pdfft?md5=872f44ce832e9d7fb0cf35da0ff3d221&pid=1-s2.0-S2772947824000392-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting hepatocellular carcinoma growth and metabolism: A synergistic approach with para-toluenesulfonamide and radiofrequency ablation","authors":"Na Liu ,&nbsp;Jianzeng Zhang ,&nbsp;Jiaojiao Wu ,&nbsp;Fan Feng ,&nbsp;Yantao Chai ,&nbsp;Yongwu Li ,&nbsp;Bo Liu","doi":"10.1016/j.iliver.2024.100111","DOIUrl":"10.1016/j.iliver.2024.100111","url":null,"abstract":"<div><h3>Background and aims</h3><p>Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal forms of cancer, posing challenges to standard treatment methods. Radiofrequency ablation (RFA) has emerged as a valuable technique for the local control of advanced HCC, especially in cases unsuitable for surgical resection. Para-toluenesulfonamide (PTS) has demonstrated antitumor properties in various cancers, yet its efficacy against HCC remains underexplored. The present study aims to investigate the therapeutic potential of PTS in HCC and examine potential synergistic effects with RFA.</p></div><div><h3>Methods</h3><p>PTS was injected directly into subcutaneous tumor tissues and its effects on cell survival, gene expression, and metabolic activity in HCC cells were evaluated. The effect of PTS and RFA in combination on HCC growth was examined using a nude mouse model of subcutaneous HCC. Data were visualized using heat maps.</p></div><div><h3>Results</h3><p>PTS inhibited the survival of HCC cells in a dose-dependent manner, modulating the expression of key genes related to cell survival, apoptosis, epithelial–mesenchymal transition, and proliferation. The combination of PTS and RFA markedly enhanced the inhibition of HCC tumor growth and induced alterations in cellular metabolism.</p></div><div><h3>Conclusion</h3><p>Combining PTS and RFA may be a promising approach to improve the efficacy of HCC treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100111"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000367/pdfft?md5=b0e8499504bb732be1b53d5b3ef270e3&pid=1-s2.0-S2772947824000367-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities","authors":"Gong Feng ,&nbsp;Ya-Fei Fan ,&nbsp;Ru-Xin Li ,&nbsp;Giovanni Targher ,&nbsp;Christopher D. Byrne ,&nbsp;Ming-Hua Zheng","doi":"10.1016/j.iliver.2024.100113","DOIUrl":"10.1016/j.iliver.2024.100113","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100113"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000380/pdfft?md5=900c268f6fb3052db25147560b9aa2ec&pid=1-s2.0-S2772947824000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic treatment in unresectable hepatocellular carcinoma: The most concerns","authors":"Jian-Hong Zhong,&nbsp;Kang Chen,&nbsp;Ze Su,&nbsp;Shao-Ping Liu,&nbsp;Fan-Jian Zeng,&nbsp;Lin Ye,&nbsp;the GUIDANCE investigators","doi":"10.1016/j.iliver.2024.100112","DOIUrl":"10.1016/j.iliver.2024.100112","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100112"},"PeriodicalIF":0.0,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000379/pdfft?md5=520af061d7f9f40ec565cf72ac9acec5&pid=1-s2.0-S2772947824000379-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimising postoperative surveillance for hepatocellular carcinoma: Beyond histological predictors","authors":"Jiahao Xu ,&nbsp;Lihui Gu ,&nbsp;Tian Yang","doi":"10.1016/j.iliver.2024.100110","DOIUrl":"10.1016/j.iliver.2024.100110","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100110"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000355/pdfft?md5=08e6e95a553cdb667d6ca485e4835264&pid=1-s2.0-S2772947824000355-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic research on MASLD: New insights into cardiovascular disease and cancer risk","authors":"Ming Yang,&nbsp;Juan Liu","doi":"10.1016/j.iliver.2024.100108","DOIUrl":"10.1016/j.iliver.2024.100108","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100108"},"PeriodicalIF":0.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000331/pdfft?md5=45e308ef2f4897a9eff0d22fcfb13eeb&pid=1-s2.0-S2772947824000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody","authors":"Shichuan Tang ,&nbsp;Tingfeng Huang ,&nbsp;Cong Luo ,&nbsp;Jun Fu ,&nbsp;Kailing Zhang ,&nbsp;Qingjing Chen ,&nbsp;Jie Kong ,&nbsp;Jianxi Zhang ,&nbsp;Zhenghong Sun ,&nbsp;Yongkang Diao ,&nbsp;Kongying Lin ,&nbsp;Yongyi Zeng","doi":"10.1016/j.iliver.2024.100109","DOIUrl":"10.1016/j.iliver.2024.100109","url":null,"abstract":"<div><h3>Background</h3><p>Tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies in combination provide survival benefits for patients with unresectable hepatocellular carcinoma (uHCC). However, the tool used to determine which patients likely benefit most from this treatment strategy has not been reported. We sought to develop a prognostic scoring system based on tumor burden score (TBS) and alpha-fetoprotein (AFP) to predict the long-term prognosis of uHCC treated with TKIs and anti-PD-1 antibodies.</p></div><div><h3>Methods</h3><p>Data on patients with uHCC treated with TKIs and anti-PD-1 antibodies from multiple centers were collected. The prognostic accuracy of TBS, AFP, Barcelona Clinic Liver Cancer (BCLC), and CTA (Combined TBS and AFP) for 2-year progression-free survival (PFS) and overall survival (OS) was evaluated.</p></div><div><h3>Results</h3><p>Overall, 278 patients with uHCC treated with TKIs and anti-PD-1 antibodies were enrolled, including 48 BCLC-B and 230 BCLC-C HCC patients. CTA (AUC = 0.721 and 0.683) outperformed TBS (AUC = 0.680 and 0.621), AFP (AUC = 0.606 and 0.594), and BCLC staging (AUC = 0.551 and 0.555) in predicting PFS and OS. The 2-year PFS and OS for low CTA (low TBS/low AFP) were 65.7% and 94.4%, respectively, which were significantly higher than 21.6% and 44.9% (<em>p</em> &lt; 0.001 and <em>p</em> = 0.002), respectively, for intermediate CTA (low TBS/high AFP or high TBS/low AFP) and 8.7% and 12.1% (both <em>p</em> &lt; 0.001), respectively, for high CTA (high TBS/high AFP). Multivariable Cox regression analysis indicated that CTA grading was an independent prognostic factor for PFS and OS (referent: low CTA; intermediate CTA, HR 2.87 and 7.17; high CTA, HR 5.52 and 10.31, respectively).</p></div><div><h3>Conclusions</h3><p>CTA grading is an accurate tool for stratifying the prognosis of uHCC treated with TKIs and anti-PD-1 antibodies and may help determine which patients may benefit more from this treatment strategy.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100109"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000343/pdfft?md5=6af753a448301ae70ed3eddae4d63605&pid=1-s2.0-S2772947824000343-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B","authors":"Wen-Xin Wang ,&nbsp;Xiaoyan Li ,&nbsp;Xue-Yuan Jin ,&nbsp;Rui Jia ,&nbsp;Hong-Min Wang ,&nbsp;Shuang-Nan Zhou ,&nbsp;Xin Zhang ,&nbsp;Ying-Ying Gao ,&nbsp;Fu-Sheng Wang ,&nbsp;Junliang Fu","doi":"10.1016/j.iliver.2024.100107","DOIUrl":"10.1016/j.iliver.2024.100107","url":null,"abstract":"<div><h3>Background and aims</h3><p>To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).</p></div><div><h3>Methods</h3><p>Ninety-nine patients with serum levels of HBsAg &lt;3000 IU/mL and HBV DNA &lt;20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or &gt;1 log₁₀ IU/mL decline in serum HBsAg.</p></div><div><h3>Results</h3><p>After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusion</h3><p>An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100107"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782400032X/pdfft?md5=05062282b65b7d860c2f3674209bd868&pid=1-s2.0-S277294782400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142012970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term effects of modified ultrasonography in laparoscopic anatomical hepatectomy for hepatocellular carcinoma","authors":"Xun Wang ,&nbsp;Xuan Meng ,&nbsp;Liming Wang,&nbsp;Peng Wang,&nbsp;Zhihao Wang,&nbsp;Weiqi Rong,&nbsp;Zhiyu Lu,&nbsp;Hongguang Wang","doi":"10.1016/j.iliver.2024.100106","DOIUrl":"10.1016/j.iliver.2024.100106","url":null,"abstract":"<div><h3>Background and aims</h3><p>Laparoscopic hepatectomy is challenging, and ultrasound guidance is an effective aid but lacks standardization. This study aimed to evaluate a modified approach for laparoscopic ultrasonography to enhance surgical outcomes.</p></div><div><h3>Methods</h3><p>Between January 2020 and August 2023, 122 patients who underwent real-time ultrasound-guided laparoscopic anatomical hepatectomy for hepatocellular carcinoma were enrolled and divided into modified and traditional ultrasonography groups. The modified ultrasound application comprised intraoperative protocol-based laparoscopic ultrasonography comprising application scenarios; standardized positions for the surgeon, trocar, and probe; and the resulting standardized sections for various laparoscopic liver resections. Clinical characteristics and perioperative outcomes were compared between the two groups. Subgroup analysis was performed and comprised techniques for modified duct structure identification and portal vein branch puncture; both techniques were used in fluorescence probe-mounted laparoscopic liver resection using negative and positive staining procedures, respectively.</p></div><div><h3>Results</h3><p>The traditional and modified groups comprised 64 and 58 patients, respectively. The patients’ background characteristics were not significantly different between the groups. Surgical duration (283.4 min vs. 225.1 min; <em>p</em> &lt; 0.001), Pringle maneuver duration (47.4 min vs. 39.5 min; <em>p</em> = 0.014), bleeding volume (258.6 mL vs. 174.8 mL; <em>p</em> = 0.005), overall complication rate (31.3% vs. 15.5%; <em>p</em> = 0.041), and postoperative stay were significantly greater in the traditional vs. modified ultrasonography groups, respectively. The modified method positively affected the number of punctures, success rate of staining, intraoperative bleeding volume, and operation duration.</p></div><div><h3>Conclusions</h3><p>Modified ultrasonography improves the safety and effectiveness of laparoscopic hepatectomy. Ultrasonography is pivotal, especially in fluorescence probe-assisted laparoscopic liver resection.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 3","pages":"Article 100106"},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000318/pdfft?md5=be0303c5aa9e5b1f82a1533c9b8ebe58&pid=1-s2.0-S2772947824000318-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141708607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype","authors":"Huigang Li ,&nbsp;Jianyong Zhuo ,&nbsp;Peiru Zhang ,&nbsp;Jinyan Chen ,&nbsp;Zuyuan Lin ,&nbsp;Xudong Yang ,&nbsp;Ruijie Zhao ,&nbsp;Chenghao Cao ,&nbsp;Wei Shen ,&nbsp;Chiyu He ,&nbsp;Hao Chen ,&nbsp;Ting Lv ,&nbsp;Xuyong Wei ,&nbsp;Shusen Zheng ,&nbsp;Xiao Xu ,&nbsp;Di Lu","doi":"10.1016/j.iliver.2024.100096","DOIUrl":"10.1016/j.iliver.2024.100096","url":null,"abstract":"<div><h3>Background and aims</h3><p>Cytokeratin 19–positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype with poor outcomes. The initiation and development of CK19+ HCC in the background of liver cirrhosis remains unclear. This study investigated the role of the cirrhosis-related gene C–C motif chemokine ligand 16 (CCL16) in the development of CK19+ HCC.</p></div><div><h3>Methods</h3><p>Datasets from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were analyzed to screen and validate the genes associated with CK19+ HCC. A total of 102 HCC patients were included for tissue microarray analysis. Gain-of-function experiments were conducted to investigate the biological functions of CCL16. CIBERSORT was used to investigate the correlation of CCL16 and immune infiltration.</p></div><div><h3>Results</h3><p>GEO dataset analysis showed that CK19+ HCC had lower expression of CCL16. In both TCGA dataset and our HCC cohort, CCL16 expression was negatively correlated with CK19 expression (<em>P</em> ​&lt; ​0.05) and its expression was higher in para-tumor than tumor tissues (<em>P</em> ​&lt; ​0.001). Moreover, low CCL16 expression was related to advanced stage and poor overall survival (<em>P</em> ​&lt; ​0.05). CCL16 overexpression downregulated CK19 expression and impacted the sphere formation ability of HCC cells. Overexpression of CCL16 inhibited the cell proliferation, migration, and invasion of HCC cell lines. Immune analysis showed HCC with high CCL16 expression had more infiltration of mast cells. HCC patients with both low CCL16 expression and low mast cells had the worst prognosis (<em>P</em> ​&lt; ​0.001).</p></div><div><h3>Conclusion</h3><p>Our data indicated that CCL16 downregulated the expression of CK19 and inhibited the malignant phenotype of HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 2","pages":"Article 100096"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947824000215/pdfft?md5=b5bdf50abc10a7dd4931f45f1e281ee8&pid=1-s2.0-S2772947824000215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}